Last reviewed · How we verify

CDDP 50

Holy Name Medical Center, Inc. · Phase 2 active Small molecule

CDDP 50 is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription.

CDDP 50 is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription. Used for Ovarian cancer, Testicular cancer, Lung cancer.

At a glance

Generic nameCDDP 50
Also known asCisplatin
SponsorHoly Name Medical Center, Inc.
Drug classPlatinum-based chemotherapy
TargetDNA
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

CDDP 50, also known as cisplatin, is a platinum-based chemotherapy drug that works by binding to DNA and forming platinum-DNA adducts, which interfere with DNA replication and transcription. This leads to cell death, particularly in rapidly dividing cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: